Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.

Antiviral therapy - 1 Sept 2001

Yerly S, Rickenbach M, Popescu M, Taffe P, Craig C, Perrin L

Abstract excerpt

OBJECTIVES: The aim of this retrospective study was to evaluate treatment outcome and characterize the pattern of genotype mutations in subjects with treatment failure on highly active antiretroviral therapy (HAART) containing nelfinavir or indinavir. STUDY DESIGN AND METHODS: The database of the Swiss HIV Cohort Study was screened for all subjects naive to protease inhibitor (PI) treatment who started HAART with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Drug Resistance, Viral

Share to HIV Protease Inhibitors

Share to Indinavir

Share to Nelfinavir

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11808753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.PMID 11808753Read ↗

Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.Semantic proximity Read ↗

Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.Semantic proximity Read ↗

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Semantic proximity Read ↗

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.Semantic proximity Read ↗

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.Semantic proximity Read ↗

HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens.Semantic proximity Read ↗

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.Semantic proximity Read ↗

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

Prevalence and virologic consequences of HIV-1 genotype mutations detected in a cohort of 161 Italian patients receiving a nelfinavir-based highly active antiretroviral therapy.Semantic proximity Read ↗

Drug Susceptibility and Resistance Mutations After First-Line Failure in Resource Limited SettingsSemantic proximity Read ↗

Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.